 |
|
|
|
|
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Alder BioPharmaceuticals, Inc.
| | | | | Phone: | (425) 205-2900 | | Fax: | (425) 205-2901 | | Year Established: | 2004 | | Employees: | 59 | | Ticker: | ALDR | | Exchange: | NASDAQ | | Main Contact: | Mark Litton, Ph.D., CBO & Treasurer | | | | Other Contacts: | Eric Carter, Ph.D., M.D., Interim CMO
Erin Lavelle, COO
Elisabeth A. Sandoval, CCO
Annette Vahratian, Senior VP, Quality
Randy Hassler, Senior VP, Pharmaceutical Operations
James B. Bucher, J.D., Senior VP & General Counsel
Larry Benedict, Executive VP & Principal Accounting Officer
Paul B. Cleveland, Interim President & CEO
Jeffrey T.L. Smith, M.D., FRCP, Senior VP, Translational Medicine
John A. Latham, Ph.D., CSO
| | | | Company Description | | Alder Biopharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder's lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). CGRP is a small protein with a well-established role in the initiation, transmission and heightened sensitivity to migraine pain. Alder's second program, ALD1613, targets adrenocorticotropic hormone (ACTH) and is intended for the treatment of congenital adrenal hyperplasia and Cushing's disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies, and an IND submission is planned for 2016. Additionally, Alder's clazakizumab is designed to block the pro-inflammatory cytokine IL-6 and has completed two successful Phase 2b clinical trials. Alder is seeking strategic opportunities for clazakizumab. | |
|
|
|
|
|
|
|
